LUNG CANCER

In this case scenario, a 59-year-old White man presented with chest pain, cough, and dyspnea. The patient was later diagnosis with non–small cell lung cancer.

In an interview prior to the NY Symposium, Perez-Soler, reviewed several areas of development in the lung cancer field that will be addressed during this year’s meeting.

During a Targeted Oncology™ Cased-Based Roundtable event, Meghan Mooradian, MD, discussed the case of a 73-year-old patient with extensive stage-small cell lung cancer.

According to early clinical trial results, taletrectinib can induce responses in patients with ROS1-positive non–small cell lung cancer.

Robert Coleman, MD, FACOG, FACS, discussed how immunotherapy in lung cancer has been widely accepted and adopted in the community oncology setting.

Compared with the median PFS reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer, the median real-world progression-free survival with durvalumab was higher.

In patients with extensive-stage small cell lung cancer, durvalumab added to platinum/etoposide chemotherapy continued to demonstrate an overall survival improvement compared with chemotherapy alone with a favorable safety profile, according to updated data from the phase 3 CASPIAN trial.

Blood-based tumor mutational burden was hypothesized to be predictive of benefit on atezolizumab treatment in patients with non–small cell lung cancer, but a study has shown otherwise.

Results from the MRTX-500 trial show that sitravatinib administered in combination with nivolumab can elicit durable response and lead to robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

Exploratory results from the phase 3 IMpower010 trial look positive fo the use of adjuvant atezolizumab in various non–small cell lung cancer populations.

In patients with advanced/metastatic non-small cell lung cancer with actionable genomic alterations, datopotamab deruxtecan, an antibody drug conjugate, demonstrated safe antitumor activity.

Can ALK inhibitors have the same impact on other malignancies that harbor ALK rearrangements as is has on non–small cell lung cancer?

Compared indirectly with real-world data of patients treated with standard of care, mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy.

A 52% reduction in the risk of disease progression or death and a 56% reduction in the risk of intracranial progression was seen with brigatinib compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts, leading to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in Japanese patients with non–small cell lung cancer.

Retrospective research suggests a survival benefit with frontline Sequential crizotinib followed by alectinib in ALK-positive non–small cell lung cancer.

The FDA has granted approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic EGFR exon 20 insertion–mutant metastatic non–small cell lung cancer, as detected by an FDA-approved test, and who have received prior platinum-based chemotherapy.

During a Targeted Oncology Case-Based Roundtable event, Hossein Borghaei, DO, MS, moderated a discussion about a 59-year-old man with non–small cell lung cancer.

Findings from the S1619 trial signal that a neoadjuvant triplet is safe and effective for the treatment of resectable mesothelioma.

During a Targeted OncologyTM Case-Based Roundtable event, Dan J. Raz, MD, MAS, and peers discussed the challenges of testing in lung cancer and treatment.

Data from an exploratory analysis of the phase 3 IMpower010 trial show the disease-free survival benefit of adjuvant atezolizumab in the treatment of early-stage non–small cell lung cancer.

The first patient has been dosed in the phase 1b/2 trial of ERAS-007, an extracellular signal-regulated kinase inhibitor, for the treatment of advanced non-small cell lung cancer.

The addition of ramucirumab to gemcitabine in the second-line setting led a survival advantage for patients malignant pleura mesothelioma.

During separate virtual live events, David R. Gandara, MD, and Alexander Spira, MD, PhD, discussed the timing of durvalumab in non–small cell lung cancer from the PACIFIC trial with participating physicians.

An otherwise healthy 60-year-old woman, who has quit smoking for 8 years after 13 pack years, presented with a nonproductive cough. The patient was diagnosed with non–small cell lung cancer. Oncologists discuss the scenario during a Case-Based Roundtable event.